지식 홈 인류 보건 지식 All 의견 종이 대중 과학 면접 필터 Therapeutic areasCOVID-19소화기 건강 Apply 홈 인류 보건 지식 Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19 홈 인류 보건 지식 Preclinical evaluation of PHH-1V candidate against SARS-CoV-2 in non-human primates 홈 인류 보건 지식 Immunogenicity and safety in pigs of PHH-1V, a SARS-CoV-2 RBD fusion heterodimer vaccine candidate 홈 인류 보건 지식 Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2 홈 인류 보건 지식 Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial 홈 인류 보건 지식 Safety and immunogenicity of PHH-1V as booster vaccination through the Omicron era: results from a phase IIb open-label extension study up to 6 months 홈 인류 보건 지식 Immunogenicity and safety of an Omicron XBB.1.16 adapted vaccine for COVID-19: Interim results from a randomized, controlled, non-inferiority clinical trial 홈 인류 보건 지식 Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2 홈 인류 보건 지식 RBDCOV Talks HIPRA’s participation: In 5 minutes, what is a recombinant protein vaccine? 더 로드하기
